Bausch + Lomb Halts Glaucoma Eye Drop Program After Pivotal Trial Failure
BLCO•Bausch + Lomb halted its glaucoma eye drop program after the investigational drug failed to meet primary endpoints in a pivotal Phase 3 trial, triggering an after-hours share selloff. The move removes a late-stage ophthalmology candidate that had been expected to expand the company’s revenue base.
1. Trial Failure Prompts Program Halt
Bausch + Lomb’s investigational glaucoma eye drop did not achieve its primary endpoints in the pivotal Phase 3 study, leading management to discontinue the program and remove the candidate from its late-stage development portfolio.
2. Pipeline Gap and Stock Impact
Discontinuation of the glaucoma drop creates a notable gap in the ophthalmology pipeline, and the unexpected trial outcome sparked a sharp after-hours decline in the company’s share price as investors reevaluate growth prospects.
